// App-Quantinova.ai

P3-11-10 : Health-related quality of life (HRQoL) in monarcHER: Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in HR+, HER2+ advanced breast cancer

Researchers

Presenter

  • Sara M Tolaney

Principal Investigators

  • Andrew M Wardley

  • Stefania Zambelli

  • John F. Hilton

  • Tiffany A Troso-Sandoval

  • Francesco Ricci

  • Seock-Ah Im

  • Sung-Bae Kim

  • Stephen RD Johnston

  • Arlene Chan

  • Shom Goel

  • Kristen Catron

  • Zhengyu Yang

  • M. Corona Gianford

  • Gregory L Price

  • Fabrice Andr

Medical Centers

  • Dana-Farber Cancer Institute, Boston, MA

  • The NIHR Manchester Clinical Research Facility at The Christie NHS Foundation Trust and Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Manchester, United Kingdom

  • IRCCS Ospedale San Raffaele, Milan, Italy

  • The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Institute Curie, PSL Research University, INSERM, Paris, France

  • Seoul National University College of Medicine, Seoul, Korea

  • Surgery, , Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of

  • The Royal Marsden Hospital, London, United Kingdom

  • Breast Cancer Research Centre - WA & Curtin University, Perth, Australia

  • Eli Lilly and Company, Indianapolis, IN

  • Institut Gustave Roussy, University of Paris Sud, Villejuif, France

Locations

  • United States

  • United Kingdom

  • Italy

  • Canada

  • France

  • Republic of South Korea

  • Australia

Companies

  • Eli Lilly and Compan

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • Abemaciclib

  • Fulvestrant

  • Trastuzumab

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • II

Study Id's

  • NCT02675231

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved